Innovation Leads the Way, Pooling Strength for a “Metamorphosis”: Part Two of a Series Highlighting Shijiazhuang Sihua Pharmaceutical Group’s Achievements in High-Quality Development


Category:

发布时间:2022-08-15

【概要描述】 Sweat nurtures the fruits of our labor, and relentless striving makes dreams a reality. As night falls, the bright and spacious laboratories of Shijiazhuang Sihua Pharmaceutical’s R&D Center shine with countless lights. Yang Xian, head of the Innovation Department, and her colleagues are still diligently poring over the day’s experimental data and analysis. Right now, there are many, many more at Shijiazhuang Sihua who, like them, are in a race against time.
Sweat nurtures the fruits of our labor, and hard work makes dreams come true.
As night falls, the bright and spacious laboratories of Shijiazhuang Sihua Pharmaceutical’s R&D Center are aglow with artificial light. Yang Xian, head of the Innovation Department, and her colleagues remain diligently at their workstations, sorting through the day’s experimental analysis data. At present, there are many, many more Shijiazhuang Sihua employees like them—people who are “racing against time.”
At the Shijiazhuang Sihua Pharmaceutical plant in the Shijiazhuang High-tech Industrial Development Zone, a striking banner reading “View Yesterday as Behind Us; Treat Today as Our Starting Point” is prominently displayed atop the imposing main building, drawing particular attention due to its proximity to Huai’an Road.
While the lofty slogan may seem simple, putting it into practice is no easy feat. At Shijiazhuang No. 4 Pharmaceutical, where “innovation” is ingrained in our very DNA, we demonstrate this commitment every single day through our actions.
 
R&D Innovation “Blossoms at Every Turn”
Continuously Adding “Weight” to Enterprises’ Transformation and Upgrading
 
Innovation is the “soul” of an enterprise and the powerful “engine” driving the high-quality development of Shijiazhuang’s biopharmaceutical industry.
Guided by innovation, Shijiazhuang Sihua Pharmaceutical has diligently strengthened its internal capabilities, boldly tackled critical “bottleneck” technologies, and developed high-performance products, continuously adding new momentum to the company’s transformative upgrade from a single-industry dominance to diversified growth.
“I am currently leading the R&D of five first-in-class innovative drugs, and right now we are working on the ADN-9 project (code name)—a first-in-class innovative drug for treating liver fibrosis jointly developed by Sihua Pharmaceutical and Zhengzhou University. If it is successfully launched, it will fill a critical gap in the domestic market!” Yang Xian told the reporter enthusiastically as soon as they met.
“Currently, we are enhancing the bioavailability of this innovative drug by optimizing its formulation process, with the ultimate goal of overcoming the bottleneck in bioavailability,” said Yang Xian. According to preliminary research, ADN-9 exhibits outstanding characteristics such as high efficacy, low toxicity, and multi-target synergistic action, making it highly promising for the treatment of the complex disease of liver fibrosis.
The reporter followed Yang Xian as she briskly entered a laboratory. She remarked with emotion, “Every day feels like there isn’t enough time. We have to make the most of every minute and second to complete the Phase I clinical trial application for this project as soon as possible, so that we can translate our research findings into practical applications that benefit both society and industry.”
“R&D innovation is a long-term endeavor that demands sustained dedication and hard work; it cannot be achieved overnight,” said Sun Lijie, Executive President of Shijiazhuang Sihua Pharmaceutical Group and General Manager of its R&D Center. He explained that the company has set its sights on the cutting edge of the industry and market needs, articulating a clear R&D strategy that integrates generic drug development with innovative research, emphasizes distinctive strengths, and prioritizes key areas. To implement this strategy, the company has strengthened top-level planning and systematic benchmarking, while coordinating the development and research of generic drugs, innovative medicines, specialty APIs, and products undergoing consistency evaluation. Leveraging the city’s pioneering policies designed to support breakthroughs in the biopharmaceutical sector, Shijiazhuang Sihua has bolstered the construction of innovation platforms such as the National Enterprise Technology Center and the National–Local Joint Laboratory, and has continuously increased its R&D investment—now accounting for nearly 10% of sales revenue. This relentless pursuit of innovation is accelerating the transformation of Shijiazhuang Sihua’s product portfolio from “whether we have it” to “how good it is,” and shifting its R&D efforts from generic development toward original, groundbreaking innovation. As a result, an increasing number of complex formulations and innovative drugs are being steadily incorporated into the company’s R&D pipeline.
Currently, Shijiazhuang Sihua Pharmaceutical has 195 projects in development, including three Class 1 new drugs for the treatment of liver fibrosis, pulmonary arterial hypertension, and other conditions that have either received clinical trial approval or submitted applications for such approval, with an additional 119 new products awaiting approval. In the first half of this year, the company secured approval for a total of 22 new products, including China’s first generic version of bupropion tablets and acetaminophen-mannitol injection—exceeding last year’s total and marking the beginning of a concentrated period of innovation-driven成果 harvest. The company’s R&D efficiency and output in specialty generic drugs rank among the highest among pharmaceutical enterprises nationwide. Leveraging innovation to enhance the application and commercialization of intellectual property, Shijiazhuang Sihua Pharmaceutical has now filed a cumulative total of 326 patent applications, with 200 patents granted, including 91 invention patents, and has been recognized as a National Intellectual Property Advantage Enterprise and a Pilot Enterprise for Industrial Intellectual Property Application. All 42 new products approved since last year have been successfully launched, achieving a 100% industrialization rate and providing strong momentum for the company’s high-quality development.
Today, 80% of Shijiazhuang Sihua Pharmaceutical’s profits are generated by new or upgraded products. Innovation has powerfully enabled the continuous optimization and upgrading of the company’s product mix and portfolio, with its products now sold in 90 countries and regions worldwide, thereby driving the enterprise’s industrial chain toward the mid- to high-end segments of the value chain.
 
Smart Manufacturing Abounds with “New Ideas”
Enhancing Quality and Efficiency to Strengthen the “Muscles and Bones”
 
Innovation knows no bounds, and it is not confined to the realm of scientific research.
Throughout the industrialization process, Shijiazhuang Sihua Pharmaceutical has consistently adhered to the principle of prioritizing innovation, ensuring that every aspect—whether production processes or equipment and facilities—incorporates innovative solutions and delivers standout achievements.
Upon entering the formulation production building of Shijiazhuang No. 4 Pharmaceutical, the reporter could see state-of-the-art, fully automated and intelligent equipment everywhere through the glass curtain wall of the visitor corridor.
“This is the BFS three-in-one plastic-bottle, ampoule, and water-for-injection production workshop. This fully automated production line integrates bottle-making, filling, and sealing into a single, seamless process within a single cleanroom environment, with a daily output capacity of over one million units,” said Jiang Deguang, Deputy General Manager of the Manufacturing Center at Shijiazhuang Sihua Pharmaceutical Group, as he pointed to the equipment behind the glass curtain wall.
In the intravenous infusion production workshop, from the preparation of injection-grade water to the automated logistics and distribution system, the reporter gained a profound appreciation for the transformative power of smart manufacturing in boosting production efficiency and enhancing product quality.
“The centralized compounding system is the ‘heart’ of the production workshop, responsible for formulating pharmaceutical solutions of various specifications and formulations. This process is completed with a single click—just one command,” explained Jiang Deguang outside the main control room of Workshop 103. He went on to say that the workshop employs a state-of-the-art, internationally leading closed-particle-conveying, online-weighing, fully automated computer-controlled compounding system, which minimizes human-induced contamination, boosts product yield, and enables more precise, efficient, and safe management of the production process.
“We have invested heavily in smart manufacturing, taking the lead in the industry by building a seamlessly integrated intelligent information management system. Over 80% of our production workshops now operate with smart manufacturing capabilities, and thanks to this transformation, the commercialization of innovative R&D outcomes has gained tremendous momentum,” said Jiang Deguang with deep conviction.
Shijiazhuang Sihua Pharmaceutical has successively been recognized as a pilot unit for the integrated development of advanced manufacturing and modern services at the national level, as well as a benchmark enterprise for intelligent manufacturing in Hebei Province, among other prestigious designations. Intelligent manufacturing has not only given Shijiazhuang Sihua Pharmaceutical the “wings” to enhance quality and boost efficiency, but has also set a “model” for the industry, fully demonstrating its leading and driving role.
 
Innovative Mechanisms for Leveraging External Resources and Talent
Providing a Broad “Stage” for Innovative Talent ”
 
Achievement is attained through talent, and undertakings are expanded by it.
Shijiazhuang Fourth Pharmaceutical Co., Ltd. is seizing the opportunity presented by our city’s vigorous implementation of the talent-strengthening strategy, aligning its efforts with industry needs and the characteristics of high-level, application-oriented professionals. To this end, the company is collaborating with renowned universities and research institutes to jointly explore new approaches, mechanisms, and models for the cooperative training of such talent.
Since last year, Shijiazhuang Sihua Pharmaceutical has successively partnered with Academician Wang Guangji to establish provincial-level academician collaboration units, and has collaborated with the research team led by Vice President Lu Tao of China Pharmaceutical University and experts from Shenyang Pharmaceutical University on joint research and development of small-molecule compounds and first-generic drugs with distinctive features. At the same time, the company has actively established a mechanism for the joint cultivation of talent between universities and enterprises, partnering with China Pharmaceutical University, Shenyang Pharmaceutical University, Hebei Medical University, Hebei University of Science and Technology, Shijiazhuang College, and other institutions to jointly build internship and practical training bases for undergraduate students. This year, Shijiazhuang Sihua Pharmaceutical has hosted more than 110 undergraduate students majoring in pharmacy-related fields for semester-long graduation internships at the company.
On July 15, Shijiazhuang Sihua Pharmaceutical Co., Ltd. held the unveiling ceremony for its university-level practice base for professional-degree graduate students and its off-campus internship and practice base for undergraduates, in collaboration with China Pharmaceutical University. Starting this fall, 12 graduate students will annually undertake a two-year program of study and practical training at Shijiazhuang Sihua Pharmaceutical, thereby actively exploring effective approaches and establishing model examples for cultivating and attracting talent for our city’s biopharmaceutical industry.
On August 8, another piece of good news was announced: the national key science and technology project—Construction and Demonstration Application of a Clinical Evaluation Technology Platform for Pediatric Drugs—in which Shijiazhuang No.4 Pharmaceutical Co., Ltd. participated, has been successfully concluded.
Seizing the favorable opportunity presented by strategic partnerships with universities and research institutes to attract high-caliber, application-oriented talent, Shijiazhuang Sihua Pharmaceutical has also placed greater responsibilities on its existing workforce, assigned them key projects, and entrusted them with team leadership, thereby emphasizing the cultivation and identification of internal talent through hands-on experience. In addition, the company has implemented a range of incentive measures—such as providing mobility allowances, offering preferential housing, and granting exceptional promotions—to ensure that researchers who are fully committed to the company’s innovation and development truly reap the sense of happiness, fulfillment, and belonging that comes from driving innovation and creation.
“Currently, our group boasts an R&D team of nearly 500 members, more than two-thirds of whom hold doctoral or master’s degrees. This year, our city has introduced a series of highly attractive new talent policies, which are extremely beneficial for us in attracting top-tier professionals,” said Tian Pengmei, Executive President of Shijiazhuang Sihua Pharmaceutical Group and General Manager of the Strategic Development and Human Resources Center. He added that this year the company has recruited another 10 doctoral graduates to take on R&D projects related to high-end and complex pharmaceutical formulations.
“To bring high-quality products to market, we must not only rely on our own R&D capabilities but also leverage external resources—drawing on expertise, intellectual capital, and favorable market conditions—to achieve leapfrog development. For instance, the key technology for osmotic pump formulations has long been a major hurdle hindering industrialization in the sector. In response, our city’s science and technology authorities have launched a ‘challenge-based’ R&D initiative aligned with the industry’s strategic layout, providing enterprises with more diverse channels and approaches for innovation and R&D.” Sun Lijie said that, thanks to supportive policies designed to benefit businesses through science and technology, three projects undertaken by local firms—including “Development and Application of Key Microjet Technology for Emulsions” and “Research and Application of Key Technologies for Osmotic Pump Formulations”—have been selected as part of the city’s first batch of challenge-based R&D projects. As a result, these companies have successfully partnered with leading experts and research teams in the field, making it only a matter of time before they overcome several critical bottlenecks.
 
Joint Efforts to “Safeguard” Enterprises in Strengthening Their Core Competencies
Boost the Biopharmaceutical Industry to Achieve Breakthroughs First
 
With a favorable wind at our backs, now is the perfect time to set sail.
“‘Innovation’ has become embedded in the very DNA of all of us at Shijiazhuang Sihua Pharmaceutical,” said Sun Lijie. He added that, moving forward, Shijiazhuang Sihua Pharmaceutical will continue to refine its innovation mechanisms, attract more top-tier innovators, and jointly pursue the path of innovation, thereby further strengthening and expanding the company and contributing to the city’s goal of building a biopharmaceutical industry cluster worth hundreds of billions of yuan.
The Municipal Party Committee and the Municipal Government attach great importance to the development of the biopharmaceutical industry, steadfastly implementing the new development philosophy in a comprehensive, accurate, and thorough manner. They are vigorously promoting breakthroughs in the biopharmaceutical sector as a priority and working to build a biopharmaceutical industrial cluster worth hundreds of billions of yuan. To this end, they have issued the “Several Measures (Trial) on Supporting Breakthroughs in the New-Generation Electronic Information Industry and the Biopharmaceutical Industry,” along with a series of targeted funding incentives and subsidies, to encourage all types of biopharmaceutical enterprises to strengthen their core competencies. At all levels and across all departments in our city, proactive measures have been taken to provide robust support and accelerate the innovative development of biopharmaceutical companies, including Shijiazhuang Sihua Pharmaceutical.
Wang Jinsheng, Chief Engineer of the Municipal Science and Technology Bureau, stated that, under the strong leadership of the Municipal Party Committee and the Municipal People’s Government, the Bureau has focused squarely on the goal of achieving breakthroughs in our city’s biopharmaceutical industry. To this end, it has provided support for Shijiazhuang Sihua Pharmaceutical’s R&D efforts by tackling critical “bottleneck” technological challenges and by fostering platform development. This year, the Bureau supported Shijiazhuang Sihua Pharmaceutical in leading the establishment of the “Research Institute for Industrial Technology of Sterile Chemical Preparations,” which has since been recognized as both a pilot municipal-level industrial technology research institute and a provincial-level industrial technology research institute for 2022. Among the first batch of 15 “challenge-based” technology-advancement projects supported by our city, three were led by Shijiazhuang Sihua Pharmaceutical, with a total funding pool of RMB 18 million. The Municipal Science and Technology Bureau will disburse corresponding rewards and subsidies to these projects, thereby helping Shijiazhuang Sihua Pharmaceutical emerge as a new benchmark for technology-driven industrial development.
Niu Xuejian, Deputy Director of the Municipal Market Supervision Administration, stated that, under the strong leadership of the Municipal Party Committee and the Municipal People’s Government, the Administration has fully leveraged its intellectual property functions to provide support to Shijiazhuang Sihua Pharmaceutical in areas such as the industrial application of patents, patent navigation, and the cultivation of high-value patents. The Administration has guided the company in establishing a patent pool for “antiviral (antibacterial) and antitumor chemical drugs,” conducting patent filings across key domains including drug ingredients, manufacturing processes, and applications to build a comprehensive protection system. This effort is accelerating the company’s high-quality development and providing robust support for achieving our city’s goal of pioneering breakthroughs in the biopharmaceutical industry.
Relevant departments, including the Municipal Bureau of Industry and Information Technology, as well as heads of industrial parks, all stated that, in the next phase, they will continue to fulfill their respective functions, proactively provide coordination and support services for enterprises, and encourage and guide more biopharmaceutical companies to fully leverage and effectively utilize the city’s suite of business-friendly policies. They will remain committed to innovation-driven development, further increase investment in R&D and technological upgrading, attract a broad pool of innovative talent, strive to overcome a number of critical “bottleneck” technologies, and rely on high-quality products and superior services to swiftly capture market share, enhance corporate core competitiveness, secure greater influence in the marketplace, and collectively make greater contributions to achieving breakthroughs in the city’s biopharmaceutical industry ahead of others and to pushing the city’s total economic output beyond RMB 1 trillion.
With the long wind at our backs, the future is full of promise!
 
Reprinted from: Shijiazhuang Daily

Keywords: